Primary cutaneous alveolar rhabdomyosarcoma: Report of a case and literature review

Villarreal‐Martínez, Alejandra; Regalado-Ceballos, Airam; Candiani, Jorge Ocampo; Vazquez-Martínez, Osvaldo; Herz‐Ruelas, Maira Elizabeth; Gómez‐Flores, Minerva; Muñoz-Garza, Fania Zamantta; Chávez‐Álvarez, Sonia

doi:10.1111/ijd.15980

Cited by 1 publication

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other nonrhabdomyosarcoma soft tissue sarcomas (NRSTS) include extrarenal rhabdoid tumors [26], Ewing, and synovial sarcomas [27]. This section will focus on RMS as it is far more prevalent and while uncommon, can metastasize to, directly invade, or primarily involve the skin [1,28,29]. Important prognostic indicators are subtype (embryonal subtype with best prognosis), age (age between 1–9-years-old at diagnosis is favorable), presence of metastasis, and presence of FOXO1-PAX fusions, the latter two yielding poor prognosis [27].…”

Section: Sarcomasmentioning

confidence: 99%

Pearls and updates: cutaneous signs of systemic malignancy

Paquette

Cotter

Huang

2022

Current Opinion in Pediatrics

View full text Add to dashboard Cite

Purpose of reviewChildren with systemic malignancies can present with concomitant dermatological manifestations. Cutaneous findings can occur before, during or after diagnosis. Recognizing these features can aid in diagnosis, inform prognosis, and help determine appropriate treatment. Following a review of the literature published over the past two years, we provide an update on cutaneous signs of pediatric systemic malignancies, concentrating on; leukemia cutis, lymphoma cutis, neuroblastoma, sarcomas, Langerhans cell histiocytosis and paraneoplastic syndromes. Recent findingsAuthors highlight the persistently heterogeneous features of cutaneous manifestations of systemic malignancy. Findings are often nonspecific, and a definitive diagnosis requires skin biopsy with immunophenotyping. Several studies describe dermoscopy features, demonstrating this as a useful tool in clinical evaluation. Genetic mutations underlying the pathogenesis of disease continue to be elucidated. Further, advances in medical treatment led to improved prognosis in many systemic malignancies, with early and aggressive treatment heralding better outcomes. SummaryComprehensive cutaneous evaluation alongside thorough clinical history and review of systems remains of paramount importance as dermatological manifestations of systemic malignancy are notoriously variable with a shared feature of often appearing benign but persisting despite usual treatment. Urgent referral to dermatology is recommended when suspicion for any cutaneous presentation of malignancy arises.

show abstract